pCD2-hTL1A-Tg

Nomenclature

C57BL/6JSmo-Tgtn(pCD2-hTL1A)1Smoc

Cat. NO.

NM-TG-250279

Strain State

Sperm cryopreservation

Export PDF

Model Description

These transgenic strains harbor pCD2-hTL1A expression cassettes.

Validation Data

image.png

Fig.1 Detection of human TL1A expression in serum by ELISA (n=3, 6 weeks old). 

Abbr. WT, wild type; N.D. not detected.

2ea10473-d338-4b4d-84b2-b92cbff4fe0d.png

Fig.2 Detection of Treg expression on CD3+T cells in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS.

 In CD3+ T cells, compared with wild-type mice, the number of Treg cells in the spleen and MLN of pCD2-hTL1A-Tg mice was increased (n=4-6, 17 weeks old).

8194dc1c-32d3-4ed6-9e2c-b0300e6a290c.png


Fig.3 Detection of CD44 expression on CD3+T cells in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS.

 In CD3+ T cells, compared with wild-type mice, the number of  CD44+ cells in the spleen and MLN of pCD2-hTL1A-Tg mice was increased (n=4-6, 17 weeks old).

45dffe14-b404-42b8-97d5-54f41d38589d.png

Fig.4 Detection of CD86 expression on CD11c+DCs in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS.

In DCs cells, the number of CD86+ cells in the spleen and MLN of pCD2-hTL1A-Tg mice was similar to that of wild-type mice (n=4-6, 17 weeks old).

00bcdd11-cf36-4b90-b6ee-1619435a9e46.png

Fig.5 Detection of CD44 expression on macrophages in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS(n=4-6, 17 weeks old).

In macrophages, the number of CD86+ cells in the spleen and MLN of pCD2-hTL1A-Tg mice was similar to that of wild-type mice.

bab2cf23-9bc8-4c1d-bc8a-5fc709323c3c.png

Fig.6 Detection of IFN-γ expression on CD4+T cells in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS.

In CD4+ T cells, compared with wild-type mice, the number of IFNγ+ cells in the spleen and MLN of pCD2-hTL1A-Tg mice was significantly increased (n=4-6, 17 weeks old).

cf6f9cfe-c09f-44c3-aecd-501d7891a921.png

Fig.7 Detection of IL-17A+ expression on CD4+T cells in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS.

In CD4+ T cells, compared with wild-type mice, the number of IL-17A+ cells in the spleen and MLN of pCD2-hTL1A-Tg mice was significantly increased (n=4-6, 17 weeks old).

372baa7d-d452-4f36-882d-6b08452b97e7.png

Fig.8 Detection of IL-4+ expression on CD4+T cells in MLN and spleen of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice by FACS.

No IL-4+ cells were observed in the spleen and MLN of pCD2-hTL1A-Tg mice and wild-type mice (n=4-6, 17 weeks old).

16991da0-bcaf-443f-aa9c-6ae1bdb61639.png

Fig. 8 Phenotype of WT (C57BL/6) mice and pCD2-hTL1A-Tg mice (n=2-3, 17 weeks old). (A) Gross photograph; (B) Colon photo; (C) Body weight and intestine index.

97f25086-6122-4fcc-87f9-351a7056ce33.png

Fig. 9 H&E staining of the small intestine and colon in pCD2-hTL1A-Tg mice (n=2-3, 17 weeks old). 

b9b8b14d-3d74-4655-b906-2ededd56de15.png

Fig. 10 Representative masson's trichrome staining images of the small intestine and colon in pCD2-hTL1A-Tg mice.  (n=2-3, 17 weeks old)


You may also like

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more